about
Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infectionSynergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida speciesCandida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicansCurrent and emerging azole antifungal agentsEffects of an acidic beverage (Coca-Cola) on absorption of ketoconazoleOral candidiasisThe 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic InfectionsEvaluation of the antimicrobial activity of ebselen: role of the yeast plasma membrane H+-ATPase.AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily.A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patientsSmall intestinal fungal overgrowthHigh-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infectionsIn vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazoleDiscovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitorsUpregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitorsStrong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent.In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformansIn-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolatesIn vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolatesComparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assaysTreatment of murine disseminated candidiasis with L-743,872In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida sppIn vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformansInhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compoundsMultiple efflux mechanisms are involved in Candida albicans fluconazole resistanceComparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusionOpportunistic infections in HIV disease.Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001Prophylactic fluconazole promotes reepithelialization in full-face carbon dioxide laser skin resurfacing.Mechanistic study of the photodynamic inactivation of Candida albicans by a cationic porphyrin.Determination of minumum inhibitory concentrations of Candida species isolated from vaginal swab specimens by using broth macrodilution and E-test.Photodynamic inactivation of fibroblasts by a cationic porphyrin.Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasisRapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing.The ins and outs of DNA fingerprinting the infectious fungiIsolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerComparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of Cryptococcus neoformans.
P2860
Q24234875-88DB1508-CCFC-49BE-B811-17AF226D9405Q24549843-76081B7F-FFBB-45DC-9F72-7916E67C5C8EQ24550731-F19AFBFC-984A-417C-9417-78D216D2DA47Q24550733-9B25A865-2926-406A-843E-51CCDABE7426Q24676913-DCF6A52B-2D3E-427D-B38B-070BA56CD5C6Q24680431-4427D98B-3E17-4330-949F-38E96D0F26C1Q26751038-0BBC444C-1321-4E85-B04A-A85CF3C52BC7Q27930289-F86BCF9B-A009-48E8-8B22-53CCDEB3F6B6Q27930958-190ADDDD-F610-4864-8859-8AAC7779964BQ28189320-1CC9BD1C-3ECA-4371-857B-90C5A92C7BACQ28259100-9E52A3DD-3703-4804-9C20-2FBCB137255AQ28292927-B239C028-BBCD-4E0A-BC0F-D1221C1117EBQ28343297-F787AAAD-2A96-463E-9D9B-8463C40C60CAQ28343863-7082DA42-C5A1-4832-9C52-C26AB2B6CBABQ28344744-24A2E383-BC1D-451A-BCFB-9C8A0DAA9C7EQ28345157-7C33FC22-F9EF-4584-A042-88CF9D63124FQ28345161-F2096341-6FF9-418E-AA0E-F6CCF96254AEQ28353303-79A55A73-4E16-4002-9D1E-55047B28990FQ28373675-C2FD9625-AAF0-49E1-815D-4156FD2317F9Q28378977-ADF86DE6-0357-46C5-884C-7640868DC9CDQ28378998-B13F9D84-2624-4CC2-8953-6926B215DE63Q28379078-76532D61-F479-4E3B-8E67-BF35FCB1EC93Q28379320-B1D36B5B-46D4-4CC5-BC54-DA270C9746B5Q28379512-F9903D77-AAE7-4DDA-94E3-3A46D509B915Q28379526-CB1880E3-34F4-48D7-893D-0FF344513405Q28379616-91503880-05EC-43C4-B90D-BB0B7AC251C9Q28379619-15CAD6A3-3CEA-4E10-8245-0B691B7835E4Q30311996-C4086E17-D34D-4578-9857-0B7606414748Q30391927-24A8CDC6-10AF-41A1-8E7C-742B169AFB5CQ30452998-1356A101-EC03-4D0B-83EF-CA749756347AQ30841110-F45260B6-D263-4411-9664-E3B4D9E933A9Q31163998-0731663F-D6BB-4C51-9B2C-05B00471F6CDQ32100597-2EA6EB49-C287-424A-B03E-3AB0FB439961Q33216603-6F9406F1-90C7-4BE1-9D48-9774E482AC1CQ33359301-57C9998F-E79B-462F-84FC-0A2933FC7EF5Q33493582-B7C1B24E-5A04-4395-BB97-184B3FD66B2EQ33555593-E0E576D6-BEA2-4DFF-92D2-A12478174444Q33634941-30F149F1-CB25-40FC-A220-8EC9942BF786Q33650105-95A56A58-4D0E-4BD5-9473-BE1BEE91F5F9Q33666286-03FA940F-9DBA-4941-A8EF-EC01DB19252E
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Resistance of Candida species to fluconazole
@ast
Resistance of Candida species to fluconazole
@en
type
label
Resistance of Candida species to fluconazole
@ast
Resistance of Candida species to fluconazole
@en
prefLabel
Resistance of Candida species to fluconazole
@ast
Resistance of Candida species to fluconazole
@en
P2860
P356
P1476
Resistance of Candida species to fluconazole
@en
P2093
M A Pfaller
M G Rinaldi
P2860
P356
10.1128/AAC.39.1.1
P407
P50
P577
1995-01-01T00:00:00Z